The evaluation over efficacy of gedatolisib, a PI3K and mTOR inhibitor, in combination with talazoparib (PARP inhibitor) in TNBC or BRCA1/2 positive breast cancer with HER2 negative was conducted in a phase II clinical trial. This evidence concerns the gene BRCA1 and breast cancer.